Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s153. https://doi.org/10.25251/skin.7.supp.153